

## A practical guide for serologic evaluation of autoimmune connective tissue diseases

Diya F. Mutasim, MD, and Brian B. Adams, MD *Cincinnati, Ohio*

Serologic testing is important in the evaluation of patients with autoimmune connective tissue diseases (CTD). There are many techniques. Each of the tests has different sensitivity and specificity with varying diagnostic value. These serologic tests detect antibodies to numerous cellular components. The diagnostic significance and specificity of each antibody vary. Choosing the appropriate test and understanding its clinical utility is an important aspect in the diagnostic evaluation of patients with CTD. (J Am Acad Dermatol 2000;42:159-74.)

**Learning objective:** At the conclusion of this learning activity, participants should be familiar with the various serologic tests for CTD, should understand the associations of specific antibodies with individual CTD, and should identify the factors that influence the predictive value of these serologic tests.

Connective tissue diseases (CTDs) are a group of autoimmune disorders that have overlapping clinical features (Table I). The accurate diagnosis of a patient with one of these disorders depends on the evaluation of 4 parameters, namely clinical findings, histopathology, tissue immunofluorescence, and serologic testing. This article is limited to the serologic evaluation. Serologic testing does not substitute for evaluation of the other criteria. Serologic testing does help to confirm a clinical diagnosis and classify subsets of a CTD and thus help predict prognosis. For example, a patient who presents with cutaneous lupus erythematosus and who is found to have significantly high antibody titer to native DNA (nDNA) (or double-stranded DNA [dsDNA]) likely has systemic lupus erythematosus (SLE) with cutaneous involvement.<sup>1-4</sup> In addition, a patient who has cutaneous sclerosis, calcinosis, and esophageal dysmotility and who is found to have anticentromere antibodies is much more likely to have a benign course associated with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiect-

asia)<sup>5,6</sup> rather than the usually severe course associated with systemic sclerosis (SSc).

### BIOLOGY OF THE ANTIBODY SPECIFICITY

Patients with CTD have an autoimmune phenomenon that results in the production of antibodies against several self-antigens. These autoantibodies are directed against all cellular components, that is, nuclear, cytoplasmic, and cell membrane molecules. The binding of these antibodies to commercially available tissue extracts is the basis for serologic testing. Whether these antibodies play a role in the pathogenesis of the clinical manifestations of the disease is suspected but not confirmed with certainty. The most common antibodies that are of diagnostic value are shown in Table II.

In evaluating the results of these tests, it is important to be aware of two findings. First, some of the antibodies are not unique to patients with CTD and may be present in the sera of normal persons or persons with other conditions.<sup>7-14</sup> Therefore the mere detection of these antibodies does not always indicate a CTD. In general, however, the total amount of antibodies to a certain antigen is much larger in patients with CTD.<sup>9,10</sup> The total amount of antibodies is usually indicated by the titer or the absolute value given to the test. Second, the specificity of each of the antibodies for the various CTD varies. For example, some antibodies, such as Sm antibodies and dsDNA antibodies, are highly specific (for SLE).<sup>11-21</sup> Other antibodies (eg, single-stranded DNA

From the Department of Dermatology, University of Cincinnati College of Medicine.

Reprint requests: Diya F. Mutasim, MD, Professor and Chairman, Department of Dermatology, University of Cincinnati, PO Box 670592, Cincinnati, OH 45267-0592. E-mail: mutasdf@email.uc.edu.

Copyright © 2000 by the American Academy of Dermatology, Inc. 0190-9622/2000/\$12.00 + 0 16/2/103582

**Table I.** Autoimmune CTDs

- 
1. LE
    - A. Systemic LE
    - B. Discoid LE
    - C. Subacute cutaneous LE
    - D. Neonatal LE
    - E. Overlap of two or more LE subsets
    - F. Overlap of LE with other CTDs
  2. Scleroderma
    - A. Cutaneous scleroderma (morphea)
    - B. Systemic scleroderma
      1. Limited disease (acrosclerosis, CREST syndrome)
      2. Diffuse disease (SSc)
  3. Dermatomyositis
  4. Sjögren's syndrome (primary and secondary)
  5. MCTD
  6. Overlap and undifferentiated CTD
- 

*CREST*, Calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; *CTD*, connective tissue disease; *LE*, lupus erythematosus; *MCTD*, mixed connective tissue disease; *SSc*, systemic sclerosis.

[ssDNA] antibodies) are of low diagnostic value because of their high nonspecificity<sup>17,22</sup>; they may be present in the sera of patients with most CTDs.

The type of antibodies present and the frequency of their occurrence vary among the various CTDs. For example, patients with mixed CTD (MCTD) have antibodies to nuclear ribonucleoprotein (also known as uridine-rich ribonucleoprotein [U<sub>1</sub>RNP]),<sup>8,12,13,17,22-27</sup> and patients with CREST syndrome have antibodies that are almost limited to the centromere.<sup>13,19,28,29</sup> In contrast, patients with SLE may have antibodies to several cellular antigens.<sup>7,8,11,12,17,19,21,22,26</sup> Fig 1 reveals the frequency of the various autoantibodies in 6 selected CTDs. Each CTD has a unique profile of antibodies.

### TECHNIQUES FOR SEROLOGIC TESTING

The methods for the detection of the various antibodies have changed over the past few decades. Immunologic techniques that are commonly used during each time period have been utilized for the detection of these antibodies. For example, radioimmunoassay and immunoelectrophoresis were commonly used in the past.<sup>30-36</sup> Radial immunodiffusion and immunofluorescence<sup>8,10,30,32,37-42</sup> remain of important value although both (especially the former) are being slowly replaced by newer techniques such as the enzyme-linked immunosorbent assay (ELISA).<sup>8,18,32,38,39,43-46</sup> Several types of antibodies may be detected by multiple techniques. The principles of immunofluorescence and ELISA are similar. An antigen (in the substrate) is placed on a glass

**Table II.** Antibodies in autoimmune CTDs

- 
1. Antibodies to DNA
    - A. Antibodies to nDNA (dsDNA)
    - B. Antibodies to ssDNA
  2. Antibodies to small ribonucleoproteins
    - A. Antibodies to Ro(SS-A)
    - B. Antibodies to La(SS-B)
    - C. Antibodies to U<sub>1</sub>RNP
    - D. Antibodies to Sm
  3. Antibodies to histones
  4. Antibodies to centromere
  5. Antibodies to phospholipid (cardiolipin)
  6. Antibodies to other cellular components
- 

*dsDNA*, Double-stranded DNA; *nDNA*, native DNA; *ssDNA*, single-stranded DNA; *U<sub>1</sub>RNP*, uridine-rich ribonucleoprotein.

slide or plastic plate (for immunofluorescence and ELISA, respectively). The substrate is incubated with the patient's serum. If the serum has antibodies, they will bind to the substrate. This binding is detected by a series of amplification steps that produce visible fluorescence (immunofluorescence) or a colored dye that will be detected and quantified by a machine's photometer (ELISA). Both tests may be quantitative by diluting the serum to various titers until the test is negative. The larger the titer, the higher the amount of antibody in the serum. ELISA has many advantages. It is cheaper, less labor intensive, may be used to screen a large number of sera together, is less subjective (does not need human technical interpretation), and is more sensitive.<sup>44,46</sup> ELISA, however, is less specific and results need to be interpreted with caution (see later).<sup>8,44</sup>

Radial immunodiffusion takes advantage of the ability of molecules (both antigen and antibody) to migrate through agarose gel, bind together, precipitate, and produce a visible line that indicates the presence of antibodies.<sup>47</sup> This test is less sensitive than immunofluorescence and ELISA but is more specific. For a serum to be positive by radial immunodiffusion, the serum must contain a relatively higher amount of antibodies (compared with more sensitive techniques).<sup>10,11</sup> Accordingly, the diagnostic value of a positive test by radial immunodiffusion is higher than that by ELISA because the diagnostic value of the antibodies does not solely rely on their presence, but also on their total amount.

The frequency of positivity for each of the various antibodies in the various CTDs varies among different reports. Some of the figures quoted in this article are an estimated average of the various percentages.




Fig 1. Frequency of various antinuclear antibodies. Each CTD has a unique profile.

## ANTIBODIES TO DNA

Serum DNA antibodies may recognize nDNA (double-stranded) or denatured ssDNA by testing, depending on the type of epitope within the DNA molecule that they recognize. The diagnostic significance of each of the two antibodies is different. The two types of antibodies will be discussed separately.

### nDNA antibodies

**Testing technique.** nDNA antibodies have been determined by several techniques, including radioimmunoassay.<sup>1,48-51</sup> Presently, ELISA is used more frequently than immunofluorescence. Some laboratories use indirect immunofluorescence in place of, or in addition to, ELISA. The immunofluorescence test is performed on *Crithidia lucilliae*. *Crithidia* is a hemoflagellate organism that possesses a giant mitochondrion. Concentrated mitochondrial DNA is found within the mitochondrion and is called the kinetoplast. The kinetoplast contains primarily nDNA (and histone) with no ssDNA. This organism's unique structure makes it an ideal substrate for determining the presence of antibodies to nDNA.<sup>3,4,52-55</sup> The ELISA test for nDNA uses calf thymus extract and is more sensitive than immunofluorescence.<sup>1,3</sup> The result of the immunofluorescence test is reported as positive or negative. A titer level may be determined but is usually unnecessary for diagnosis because the detection of nDNA antibodies by immunofluorescence at any titer has significant diagnostic value. The result of the ELISA is reported as a value with a range for normal values.

**Disease association.** nDNA antibodies are highly characteristic of SLE.<sup>1,2,4,12,13,17,19,48,51,56</sup> Their presence is usually associated with positive direct

immunofluorescence in the patient's normal skin (the lupus band), low circulating complement levels, renal disease, and generally poor prognosis.<sup>11,21</sup>

**Interpretation of results.** Significant levels of nDNA antibodies (positive immunofluorescence test or ELISA value higher than 2-3 standard deviations above the mean) confirm a clinical diagnosis of SLE. Low levels of nDNA antibodies may be detected in rheumatoid arthritis, Hashimoto's disease, Graves' disease,<sup>48</sup> Waldenström's macroglobulinemia,<sup>53</sup> MCTD, SSc,<sup>54</sup> autoimmune liver disease,<sup>13</sup> and Sjögren's syndrome.<sup>55</sup>

### Indications to order nDNA antibody testing.

The most practical indication to obtain nDNA antibody testing is in the setting of a patient with a clinical suspicion of SLE. Although a significantly positive test confirms the diagnosis, a negative test does not exclude SLE because nDNA antibodies are positive in only 50% to 83% of patients with SLE.<sup>40,46</sup>

### ssDNA antibodies

**Testing technique.** ssDNA antibodies are detected by ELISA.<sup>2,57-59</sup> Unlike the extracts used for nDNA antibodies, extracted nDNA molecules are further denatured to produce ssDNA molecules. The most common source of DNA used for both nDNA antibody and ssDNA antibody determination is calf thymus.<sup>2,59-61</sup>

**Disease association.** ssDNA antibodies have a very low diagnostic value. They have been detected in the sera of patients with various forms of lupus erythematosus as well as other CTDs, including dermatomyositis,<sup>62</sup> morphea,<sup>63</sup> and Sjögren's syndrome.<sup>64</sup> ssDNA antibodies are especially prevalent in linear morphea in children.<sup>65</sup> The role that the

**Table III.** Drugs reported with drug-induced SLE

---

Allopurinol <sup>76</sup>
Captopril <sup>83</sup>
Chlorpromazine <sup>69,76,77,83</sup>
Clonidine <sup>83</sup>
Danazol <sup>83</sup>
Diphenylhydantoin <sup>69</sup>
Ethosuximide <sup>69,72,76,83</sup>
Griseofulvin <sup>76,83</sup>
Hydralazine <sup>69-71,76-79,83</sup>
Isoniazid <sup>74,76,79,83</sup>
Lithium <sup>79,83</sup>
Lovastatin <sup>83</sup>
Mephenytoin <sup>76</sup>
Mesalazine <sup>75</sup>
Methyldopa <sup>79,83</sup>
Minocycline <sup>82</sup>
Oral contraceptives <sup>76,83</sup>
<i>para</i> -Amino salicylic acid <sup>74</sup>
Penicillamine <sup>76,78,79,83</sup>
Penicillin <sup>83</sup>
Phenothiazines <sup>79</sup>
Phenylbutazone <sup>76</sup>
Piroxicam <sup>80</sup>
Practolol <sup>76</sup>
Primidone <sup>76</sup>
Procainamide <sup>69-71,76,77,79,83</sup>
Propylthiouracil <sup>73,76,83</sup>
Quinidine <sup>76,79,83</sup>
Streptomycin <sup>76</sup>
Sulfasalazine <sup>78,79</sup>
Sulfonamides <sup>76</sup>
Tetracycline <sup>76,79</sup>
Thiamazole <sup>73</sup>
Trimethadione <sup>76</sup>
Valproate <sup>81</sup>

---

antibodies play in the pathogenesis of morphea, if any, is unknown. ssDNA antibodies as well as nDNA antibodies may play a role in some of the systemic manifestations of SLE.<sup>11,36</sup>

**Interpretation of results.** Because low levels of ssDNA antibodies may be detected in persons without CTD, a patient's level of antibodies should be much higher than the normal range (>3 standard deviations above the mean) to be of value in the diagnosis of CTD.<sup>66</sup>

**Indications to order ssDNA antibody testing.** Because ssDNA antibodies are nonspecific, their diagnostic value in the work-up of patients with CTD is low.

### Histone antibodies

Histones are basic proteins that bind the DNA helical structure to contribute to the supercoil for-

mation.<sup>67,68</sup> Histone antibodies are characteristic of drug-induced SLE. Drugs that have been reported with drug-induced SLE are shown in Table III.<sup>69-83</sup>

**Testing technique.** Histone antibodies may be detected by various assays including immunofluorescence,<sup>68,69,84-87</sup> complement fixation,<sup>68,86</sup> radioimmunoassay,<sup>68,70</sup> and ELISA.<sup>68,87-89</sup> Quantitative assays such as ELISA use commercially available histones. Immunofluorescence assay utilizes animal substrates such as rat liver.<sup>70,84,86,87</sup>

**Disease association.** Histone antibodies are characteristic of SLE. The majority (approximately 90%) of patients with drug-induced SLE<sup>69,90,91</sup> have antihistone antibodies to the exclusion of other antibodies. Approximately 30% of patients with idiopathic SLE also have antihistone antibodies.<sup>11</sup> Most of these patients, however, have other antinuclear antibodies.<sup>11,86,89</sup>

**Interpretation of results and indications to order histone antibody testing.** Histone antibody testing is indicated in patients suspected of having drug-induced SLE. Their presence strongly supports the diagnosis. Idiopathic SLE, however, cannot be excluded on the basis of the presence of antihistone antibodies.

### RNP ANTIBODIES

Of all the types of cellular RNA, autoantibodies in patients with CTD are directed to the small ribonucleoproteins (sRNP). This type constitutes the smallest portion of cellular RNA (<1% of the total RNA). sRNP consists of several molecules that contain RNA and an associated protein, thus the term *ribonucleoprotein*.<sup>26,92</sup> The protein component has enzymatic activity and plays a role in the processing of the RNA molecule.<sup>92</sup> Antibodies to sRNP are directed against epitopes within the protein component of the molecules.<sup>23,26,92-94</sup> Antibodies to various sRNP molecules are named after the name of the sRNP molecule, for example, Ro(SS-A),<sup>95-101</sup> La(SS-B),<sup>97,102</sup> U<sub>1</sub>RNP,<sup>92,94,103</sup> and Sm.<sup>104-106</sup> The exact role that these antibodies play in the pathogenesis of the associated CTD is not clear. The detection of these antibodies, however, is of value in the diagnosis of the various CTDs. The diagnostic specificity of each of these antibodies is variable. For example, Sm antibodies are characteristic of SLE,<sup>16,107</sup> whereas Ro(SS-A) antibodies have been reported in various subsets of lupus erythematosus and other CTDs.<sup>95-97,101,108-111</sup>

There are two major techniques for the detection of sRNP antibodies. The first is radial immunodiffusion, which has high specificity and low sensitivity; the other is ELISA, which has higher sensitivity and less specificity.<sup>112</sup> Most large laboratories (usually

**Table IV.** Incidence of anti-Ro(SS-A) antibodies in autoimmune CTDs (by radial immunodiffusion)<sup>11</sup>

Diagnosis	%
Antinuclear antibody negative SLE	70
Subacute cutaneous LE	70
Homozygous C2 or C4 deficiency	70
Late onset SLE	80
Neonatal LE	95
Mothers of infants with neonatal LE	95
Discoid LE	0-20
Sjögren's syndrome	50
SSc, dermatomyositis	Rare
Healthy persons	< 1

SSc, Systemic sclerosis.

national) utilize ELISA because of the advantages discussed earlier.

The interpretation of sRNP antibody testing is technique specific. As mentioned earlier, the mere presence of antibodies is of less diagnostic value than the total amount as detected by the quantitative test. Because of the lower sensitivity of radial immunodiffusion, a patient's serum needs to contain large amounts of antibody for the test to be positive. Accordingly, a positive test by radial immunodiffusion has a high diagnostic value. On the other hand, because ELISA is highly sensitive, a positive test by ELISA is of low diagnostic value. The inherent low specificity of ELISA is made up for by the ability of the test to provide a quantitative assessment of the antibodies that is provided as a value and compared with the normal range. For an ELISA result to be of high diagnostic value, the level of antibodies must be more than 2 to 3 standard deviations above the mean of the normal range.

### Anti-Ro(SS-A) and anti-La(SS-B) antibodies

**Disease associations.** Anti-Ro(SS-A) antibodies are characteristic of two CTDs, namely, lupus erythematosus and Sjögren's syndrome.<sup>27,95-97,108,109,113-115</sup> The reported incidence of this antibody varies with the technique used in the study. The incidence of positive anti-Ro(SS-A) antibody in a specific disorder is lower by immunodiffusion compared with ELISA. Most of the old reports utilized radial immunodiffusion.<sup>108-110,113,116-118</sup> The more recent reports provide incidences based primarily on ELISA testing<sup>95,108,119,120</sup> and are therefore higher than those reported by immunodiffusion. By radial immunodiffusion, anti-Ro(SS-A) antibodies are detected in approximately 50% of patients with Sjögren's syndrome<sup>11,95,96,109,113</sup> and a varying percentage of patients with the various subsets of lupus erythe-

**Table V.** Indications for anti-Ro(SS-A) and anti-La(SS-B) antibody testing\*

Work-up for photosensitivity
Screening for certain patients with LE
Suspicion of subacute cutaneous LE
Suspicion of neonatal LE
Suspicion of Sjögren's syndrome
Work-up for idiopathic chronic vasculitis
Patients with systemic or subacute cutaneous LE with negative screening fluorescent ANA test

\*References 95-97, 102, 108-110, 115-117, 121.

matusus<sup>11,96,109,110,115,116,121-123</sup> (Table IV). Anti-Ro(SS-A) antibodies are strongly associated with photosensitivity,<sup>95,96,118</sup> especially in patients with subacute cutaneous lupus erythematosus (SCLE) of the idiopathic as well as the drug-induced types.<sup>95,96,108,124-126</sup> Anti-Ro(SS-A) antibodies may be associated with a higher incidence of vasculitis.<sup>95,96,108,113</sup> There appears to be a genetic predisposition for the presence of anti-Ro(SS-A) antibodies. Patients have a higher incidence of HLA-DR3,<sup>115</sup> -DQ2,<sup>96</sup> and -DRw52.<sup>95,101</sup>

Anti-La(SS-B) antibodies are closely related to anti-Ro(SS-A) antibodies. More than 90% of sera with anti-La(SS-B) antibodies are also positive for anti-Ro(SS-A) antibodies.<sup>116</sup> The diseases associated with anti-La(SS-B) antibodies are similar to those associated with anti-Ro(SS-A) antibodies, namely, lupus erythematosus and Sjögren's syndrome. The incidence of anti-La(SS-B) antibodies in these disorders, however, is approximately half that of anti-Ro(SS-A) antibodies.<sup>101,113,116</sup>

**Indications for ordering anti-Ro(SS-A) and anti-La(SS-B) antibody testing.** There are several indications in dermatological practice to order anti-Ro(SS-A) and anti-La(SS-B) antibody testing (Table V). Anti-Ro(SS-A) and anti-La(SS-B) antibodies are occasionally helpful in the diagnostic work-up of a patient with photosensitivity,<sup>95,96,118</sup> especially when the clinical and histologic findings are not characteristic. Anti-Ro(SS-A) and anti-La(SS-B) antibody testing may also be helpful in the initial baseline evaluation of patients with cutaneous lupus erythematosus with features of photosensitivity. Anti-Ro(SS-A) and anti-La(SS-B) antibodies are helpful in confirming the clinical diagnosis of a disease that is known to be highly associated with these antibodies, such as SCLE, neonatal lupus erythematosus, and Sjögren's syndrome.<sup>11,95,96,109,124-126</sup> An occasional patient with chronic idiopathic vasculitis may be revealed to have underlying undiagnosed Sjögren's syndrome, making it appropriate to obtain testing for anti-Ro(SS-A) and

**Table VI.** Indications for fluorescent ANA testing in dermatological practice

---

Work-up for photosensitivity
Baseline in patients with discoid LE
Clinical suspicion of CTD
Baseline for phototherapy
Work-up of chronic vasculitis

---

anti-La(SS-B) antibodies in patients with chronic idiopathic vasculitis.<sup>95,96,108,113</sup> Finally, anti-Ro(SS-A) and anti-La(SS-B) antibodies are useful in the evaluation of a patient with the clinical manifestations of SLE or SCLE if the screening fluorescent antinuclear antibody (ANA) test is negative,<sup>11,117,118</sup> since the ANA test may be negative despite the presence of anti-Ro(SS-A) and/or anti-La(SS-B) antibodies.

### Antibodies to U<sub>1</sub>RNP and Sm

Antibodies to U<sub>1</sub>RNP are present in the sera of patients with MCTD and SLE. By definition, antibodies to U<sub>1</sub>RNP are detected in 100% of patients with MCTD<sup>15,23-25,127</sup> and approximately 30% of patients with SLE.<sup>92,93</sup> They have also been reported rarely in neonatal lupus erythematosus.<sup>128,129</sup> As will be discussed in more detail later, the presence of U<sub>1</sub>RNP antibodies in MCTD is to the exclusion of other types of antinuclear antibodies.<sup>23,92</sup> In contrast, patients with SLE who have U<sub>1</sub>RNP antibodies usually have ANAs with other specificities as well.<sup>92</sup> This observation is important when attempting to differentiate between MCTD and SLE. U<sub>1</sub>RNP antibodies are very rarely detected in patients with SSc.<sup>130-132</sup> Because the incidence of SLE is much higher than that of MCTD, the majority of patients with U<sub>1</sub>RNP antibodies have SLE rather than MCTD. The presence of U<sub>1</sub>RNP antibodies is usually associated with sclerodactyly, Raynaud's phenomenon, esophageal dysmotility, low incidence of renal disease, pulmonary dysfunction, arthritis, and myositis.<sup>132,133</sup>

Antibodies to Sm by immunodiffusion are diagnostic of SLE.<sup>16,107</sup> They have not been reported in patients with other CTDs. The incidence of Sm antibodies in SLE is only 15% to 40%.<sup>15,16,104,134-136</sup> Most patients with antibodies to Sm will also have antibodies to U<sub>1</sub>RNP.<sup>93,137</sup> The converse of this observation, however, is not true. Most patients with U<sub>1</sub>RNP antibodies do not have Sm antibodies.<sup>127,131</sup>

Antibodies to U<sub>1</sub>RNP and Sm are indicated when attempting to confirm the diagnosis of MCTD<sup>23-25,92,127</sup> and SLE,<sup>16,93,107</sup> respectively.

### OTHER AUTOANTIBODIES

Several other autoantibodies have been reported

in patients with CTD. The diagnostic value of most of these antibodies is limited; only two are discussed in this review. Scl-70 antibodies are directed against the enzyme topoisomerase-I.<sup>138-140</sup> This is a 100-kd basic protein that affects the tertiary structure of DNA molecules. Scl-70 antibodies are characteristic of SSc and help differentiate patients with extensive cutaneous and systemic involvement from those with limited disease.<sup>131,141-143</sup> The incidence of Scl-70 antibodies, however, is low (approximately 10%-20% by radial immunodiffusion).<sup>141,142</sup> Scl-70 antibodies may be viewed as a marker for SSc when compared with patients with CREST syndrome who have another marker antibody, namely, anti-centromere antibody (see section on fluorescent antinuclear antibody testing).<sup>5,28,142-144</sup>

Jo-1 antibodies are directed against the enzyme histidyl tRNA synthetase (150 kd) and are detected in a small number of patients with dermatomyositis (and polymyositis).<sup>145-148</sup> The presence of Jo-1 antibodies is often associated with pulmonary involvement and possibly the mechanic's hand skin lesions.<sup>147,149,150</sup>

### FLUORESCENT ANA TEST

The fluorescent ANA test is a very good screening test for most of the previously discussed antibodies.

#### Testing technique

The ANA test is an indirect immunofluorescence test that utilizes a substrate rich in nuclear material. A positive ANA test indicates the presence of ANAs. It does not indicate the specific type of antibody, although close examination of the pattern of positivity may be helpful in suggesting the specific type of ANA that is present in the tested serum.

The indications for ordering an ANA test in dermatology include the work-up of patients with photosensitivity, work-up of patients with chronic vasculitis, a baseline for patients with discoid lupus erythematosus, clinical suspicion of CTD, and baseline for patients undergoing phototherapy (Table VI).

#### Interpretation of results

When an ANA test result is obtained, 3 parameters are evaluated; these include the substrate used, the titer of a positive test, and the pattern of fluorescence.

**ANA substrate.** There are two major types of substrate for ANA testing. Until two decades ago, most ANA tests were performed on animal substrates, such as mouse kidney or rat liver.<sup>10,11,42,151</sup> Sera of some patients with SLE were reportedly negative on such substrates. It became clear that human substrates (cultured human cells) are more sensitive

**Table VII.** Conditions other than autoimmune CTDs with positive ANA

Elderly persons <sup>12,153</sup>
Pregnant women <sup>154,155</sup>
Relatives of patients with CTD <sup>12,156</sup>
Other autoimmune diseases (eg, primary biliary cirrhosis, autoimmune thyroiditis) <sup>14,196</sup>
Drugs (eg, procainamide, hydralazine) <sup>68-83,157</sup>
Chronic infections <sup>10,14</sup>
Neoplasms <sup>10,14</sup>
Healthy persons <sup>9,11,12,153</sup>

than animal substrates.<sup>11,30,32,38</sup> Most SLE sera that were negative on animal substrates were positive on human substrate. Because of this observation, most laboratories use cultured human cell substrates. Presently, the vast majority of laboratories use a specific type of cultured human cells referred to as HEp-2 cells.<sup>11,30,32,38</sup> These are obtained from cultured esophageal squamous cell carcinoma cells. The cells are available commercially, prefixed on glass slides. Because an occasional laboratory may still be using animal substrates for ANA testing, it is essential to pay attention to the substrate being used by each of the various laboratories from which a physician may receive results. A serum that is negative on animal substrate may be positive when tested on cultured human cells.

**ANA titer.** As mentioned earlier, the presence of ANAs is not diagnostic of CTD. The amount of antibody (and the specificity) have significant value in the interpretation of an ANA test.<sup>9,11,13</sup> The ANA titer is an indirect measure of the total amount of serum antibodies. The higher the titer, the higher the amount of antibodies. Generally, the ANA test is negative or very low in young and healthy persons.<sup>9,12,152,153</sup> It is generally high in patients with systemic CTD.<sup>11-13</sup> The ANA titer is intermediate in some patients with CTD as well as in persons with a wide variety of conditions (Table VII). These include old age,<sup>12,153</sup> pregnancy,<sup>154,155</sup> close relatives of patients with systemic CTD,<sup>12,156</sup> patients taking drugs that are known to induce SLE (who do not have manifestations of CTD),<sup>68-83,157</sup> and healthy persons.<sup>9,11,12,153</sup> The incidence of positive ANA in healthy persons at various titers is shown in Table VIII.<sup>9</sup> Accordingly, a titer of 1:80 or less is of no diagnostic value because of the high prevalence of positive ANA tests at such titers in the general population. A reasonable cut-off point is around 1:160 to 1:320. An ANA test at such titers or higher may help confirm the clinical diagnosis of a CTD. There are, however, healthy persons who have ANA titers above

**Table VIII.** Positive fluorescent ANA test in healthy persons (on HEp-2 cells)<sup>9</sup>

Titer	Prevalence
1:40	32%
1:80	13%
1:160	5%
1:320	3%

**Table IX.** ANA patterns and their antigen and disease associations

ANA	Predominant antigen	Disease	Reference Nos.
Peripheral	nDNA	SLE	10,14,161
Homogeneous	nDNA, histones	SLE	14,161
Nucleolar	Nucleolar RNA	SSc, SLE	14,158,161
Centromere	Kinetochore	CREST	14,159
Speckled	Various ribo-nucleo-proteins	MCTD, SLE, SSc, Sjögren's Syndrome	14,161

1:320. The diagnosis of a CTD should not be made solely on the titer of an ANA test.


**ANA patterns.** The patterns of fluorescence of the nuclei in an ANA test are usually associated with specific antinuclear antibodies (Table IX) (Fig 2).<sup>10,11,14,20,158-161</sup> For example, the peripheral or rim pattern is associated with antibodies to nDNA and thus correlates with the diagnosis of SLE. The homogeneous pattern is associated with antibodies to nDNA or antibodies to histones, which are seen frequently in patients with SLE.

#### ANA-negative SLE

ANA-negative SLE was reported in patients who had cutaneous and/or systemic manifestations of SLE, but who were negative by ANA testing on animal substrates.<sup>162,163</sup> Most of these patients were later found to have positive ANA on human substrate. Many of these patients had photosensitivity and some of them were later reported as having SCLE with anti-Ro(SS-A) antibodies.<sup>163</sup> Another reason for the ANA test to be negative in a patient with SLE is if the patient's ANAs are solely against ssDNA. Because the fluorescent ANA substrate has intact nuclei without single strands of DNA, the test is expectedly negative.

#### DIAGNOSTIC VALUE OF THE FLUORESCENT ANA TEST

There are several parameters that indicate the



**Fig 2.** The different patterns of fluorescence on HEp-2 cells include (A) peripheral, (B) homogeneous, (C) nucleolar, (D) centromere, and (E) speckled.

value of a certain test. These include sensitivity, specificity, positive predictive value, negative predictive value, and marginal benefit. Sensitivity refers to the probability of a test to have a positive result in a patient with the disease (true positives  $\div$  [true positives + false negatives]).<sup>12</sup> Specificity refers to the

probability of a test to have a negative result in a person without disease (true negatives  $\div$  [true negatives + false positives]).<sup>12</sup> Positive predictive value refers to the probability of a person with positive test to have disease (true positives  $\div$  [true positives + false positives]).<sup>12</sup> The positive predictive value is directly cor-

related with test sensitivity and prevalence of disease in the test population.<sup>12,164</sup> Negative predictive value refers to the probability of a person with negative test to be free of disease (true negatives ÷ [true negatives + false negatives]).<sup>12</sup> Tests with high specificity will have high predictive value when positive, since false positivity is very low. Tests with high sensitivity will have high predictive value when negative, since false negativity is very low. Marginal benefit of a test refers to the posttest disease probability compared with pretest probability.<sup>165</sup>

The value of the fluorescent ANA test in the diagnosis of SLE and other CTDs has been evaluated repeatedly. The primary focus of the published studies is on SLE. The sensitivity of ANA tests for SLE is very high. Almost all patients with SLE have positive ANA tests.<sup>12,19,164,166</sup> The negative predictive value for SLE is also very high. A patient with a negative ANA test is highly unlikely to have SLE.<sup>12,164,166</sup> The positive predictive value for SLE, however, is generally low, especially at low titers<sup>12,164,166,167</sup> because the specificity of the ANA test for SLE, especially at low titers, is low. As discussed earlier, a positive ANA test especially at a low titer may be seen in several conditions and persons without SLE or other CTDs.<sup>11,12,68-73,75-83,153-157</sup> In the case of a patient with clinical findings suggestive of SLE or other systemic CTDs in which the ANA test is negative or with a low titer, more selective testing for individual anti-nuclear antibodies (eg, DNA, ribonucleoprotein) may be helpful in confirming the diagnosis.

Of all the parameters to evaluate a test, the marginal benefit is of high practical value for the physician who is attempting to confirm or exclude a diagnosis by ordering a certain test. The marginal benefit of the fluorescent ANA test is minimal when the pretest probability of disease is very low or very high. For example, persons with no clinical findings to suggest SLE are highly unlikely to benefit from an ANA test. In such a setting, the test is almost invariably negative or with very low titer and thus will not confirm a diagnosis of SLE. Similarly, the marginal benefit from the fluorescent ANA test in a patient with the characteristic multiple organ involvement of SLE is low because the diagnosis is already known and the test will invariably be strongly positive. The marginal benefit of the fluorescent ANA test is maximal when the pretest probability of disease is intermediate.<sup>168</sup> For example, the diagnosis of a patient with some cutaneous and/or systemic manifestations suggestive of SLE may be confirmed or excluded by the result of an ANA test. A strongly positive ANA test will help confirm the diagnosis, whereas a negative test may exclude SLE. These observations were supported in a recent study in which the usefulness of

the ANA test was investigated in a group of more than 1000 inpatients and outpatients in whom the ANA test was ordered.<sup>164</sup> One hundred fifty-three patients with a positive ANA test were compared with an equal number of patients with a negative ANA test. Patients with positive ANA were generally older than those with negative ANA. The ANA test was ordered primarily in patients suspected of having a CTD or vasculitis. The negative predictive value was 100% for SLE and 97% for other CTDs. The positive predictive value was 11% for SLE and 22% for other CTDs. The predictive value was lower for patients who were older than 65 years compared with those younger than 65 years. The conclusion of the study was that the diagnostic value of the ANA test depends on the clinical setting in which it is ordered,<sup>164</sup> and clinicians should be aware that in the setting of a low prevalence of CTD an ANA test's positive predictive value is low.

### RECENT SCREENING ANA TESTS

In the past few years, attempts have been made to replace the fluorescent ANA test with ELISA screening tests. There have been many ELISAs that have been reported to be of value for screening ANA tests. Some of these ELISAs utilize extracts of tissue containing various nuclear components. Other ELISAs utilize molecules synthesized by recombinant technology. Some ELISAs utilize individual recombinant molecules such as Ro(SS-A), whereas others utilize combinations of various molecules to increase the sensitivity of the test. In a recent study, the performance of the various ELISA ANA tests was compared with the "gold standard" fluorescent ANA test.<sup>169</sup> Sera that were positive by fluorescent ANA test were tested by the various ELISA techniques. The agreement that a serum is ANA positive was 87% to 95% when comparing the various ELISA tests with the fluorescent ANA test results.<sup>169</sup> The sensitivity of the various ELISAs was 69% to 98% and the specificity ranged between 81% and 98%. These figures were arrived at using sera that were positive at 1:160 by the fluorescent ANA test. The above comparison figures were much lower for sera with fluorescent ANA titer of 1:40. Many ELISA techniques missed a low titer positive ANA as well as sera with specific ANAs (eg, anti-DNA antibodies). Presently, ELISA screening ANA tests may be adequate to screen sera with intermediate to high titer.<sup>169</sup> It remains to be seen whether the performance of screening ANA tests by ELISA would match that by the fluorescent technique.

### SEROLOGIC PROFILES IN CTDs

Each CTD has a rather specific autoantibody profile (Fig 1). Some of these profiles are "simple" in

**Table X.** Serologic profiles in CTDs<sup>27</sup>

Profile	nDNA	Sm	U <sub>1</sub> RNP	Ro(SS-A)	La(SS-B)	Centromere	Scl-70	Histone	Disease
A	+	+							SLE
B	-	-	+						MCTD
C	-	-	-	+	+				SS, SCLE
D	-	-	-	-	-	+	+		SSc, CREST
E	-	-	-	-	-	-	-	+	Drug-SLE

SS, Sjögren's syndrome; SCLE, subacute cutaneous lupus erythematosus.

**Table XI.** Indications for APA testing\*

Livedo reticularis  
Purpura and necrosis  
Ulcers  
Internal organ thrombosis  
Recurrent miscarriages  
Screening in patients with SLE

\*References 173, 174, 176, 182, 190, 191, 193, 194, 197, 198.

that they include one characteristic antibody (eg, anticentromere antibodies in patients with CREST<sup>5,28,29,170,171</sup> and anti-U<sub>1</sub>RNP antibodies in patients with MCTD<sup>15,23-25,127</sup>). On the other hand, patients with SLE have a larger array of autoantibodies. Some of these antibodies are highly characteristic for SLE (nDNA antibodies<sup>1,4,49,51,172</sup> and Sm antibodies<sup>15,16,104,107,134</sup>), whereas others are less characteristic (screening fluorescent ANA test,<sup>12,70,71,153-155</sup> anti-Ro(SS-A) antibodies,<sup>95-97,108-110</sup> and U<sub>1</sub>RNP antibodies<sup>23,25,93</sup>).

A recent study addressed the question whether the diagnosis of a CTD could be predicted among a group of patients suspected of having CTD and in whom extensive autoantibody testing was performed. The investigators created 5 profiles.<sup>27</sup> The 5 profiles are shown in Table X. Profiles were divided on the basis of positivity and negativity of individual ANA tests. Empty boxes in the table do not indicate negativity of those tests, but instead the irrelevance of the results of those tests. For example, profile A included patients who had antibodies to nDNA and/or antibodies to Sm.<sup>27</sup> These patients had SLE regardless of the results of their other ANA tests. Patients in profile B had antibodies to U<sub>1</sub>RNP but were negative for nDNA antibodies and Sm antibodies. These patients had the diagnosis of MCTD or SLE.<sup>27</sup> The authors comment that these SLE patients with U<sub>1</sub>RNP antibodies only may be classified by others as having MCTD. Patients in profile C were negative for antibodies to nDNA, Sm, and U<sub>1</sub>RNP, but positive for antibodies to Ro(SS-A)

and/or La(SS-B). These patients had either Sjögren's syndrome or SCLE.<sup>27</sup> Patients in profile D were negative for antibodies to nDNA, Sm, U<sub>1</sub>RNP, Ro(SS-A), La(SS-B), and positive for antibodies to centromere and/or antibodies to Scl-70. These patients had SSc or CREST syndrome.<sup>27</sup> Finally, patients in profile E were negative for all antibodies except antihistone antibodies. Patients in this group had drug-induced SLE.<sup>27</sup> These data should be helpful to the practicing physician in the interpretation of the various ANA test results.

## ANTIPHOSPHOLIPID ANTIBODIES

Antiphospholipid antibodies (APAs) are directed against negatively charged phospholipids, present in cell membranes.<sup>58,173-177</sup>

### Testing technique

APAs are detected by various techniques. These antibodies cause the biologically false positive VDRL test for syphilis.<sup>58,178,179</sup> Thus VDRL is positive in many patients with APA. These patients will have negative fluorescent treponemal antibody test. In the 1950s, these antibodies were detected in the sera of patients with SLE, by their in vitro anticoagulant properties; thus the term *lupus anticoagulant* has been used<sup>177,180</sup> and remains one of the methods to assay for APA. Sera containing APAs delay the coagulation pathway of normal blood in vitro. It is interesting that the presence of the antibodies is associated clinically with thrombosis rather than bleeding diathesis. The most frequently used assay for APA is ELISA using bovine cardiolipin.<sup>58,180-183</sup> The term *anticardiolipin antibodies* is frequently used interchangeably with APAs. The sensitivity of the lupus anticoagulant assay and ELISA for anticardiolipin antibodies is 75% to 90% each.<sup>174,176</sup> It is interesting that some sera may be positive by one assay and negative by the other. Because of the high degree of sensitivity of the ELISA, it has been recommended as the screening test for APA. If the ELISA is negative in a patient who is highly suspected of having APA, the lupus anticoagulant assay may be obtained.<sup>176,182</sup>

## Disease association

APAs are most prevalent in patients with SLE (approximately 50%).<sup>58,173,174,178,184,185</sup> Patients with other CTDs have a lower prevalence of these antibodies. APAs may also be seen in patients taking certain drugs (cocaine, interferon alfa, procainamide, hydralazine, phenothiazines, quinine, quinidine, fansidar, and phenytoin<sup>182</sup>), patients with chronic infections (syphilis, infectious mononucleosis, tuberculosis, leprosy, leptospirosis, malaria, typhus, trypanosomiasis,<sup>173</sup> schistosomiasis and filariasis,<sup>186</sup> cytomegalovirus infection,<sup>187</sup> HIV infection,<sup>188</sup> hepatitis C<sup>189</sup>), and occasionally in persons who do not have an associated condition (primary APA syndrome<sup>174,190</sup>). APAs have been associated with arterial and venous thrombosis in various organs, including the central nervous system, the heart, and the skin.<sup>173,174,176,182,191-193</sup> Young women with APAs are predisposed to recurrent miscarriages.<sup>173,174,176,182,192</sup> Many patients with APAs have thrombocytopenia. Patients with APAs who present to dermatological practice usually have livedo reticularis, purpura, necrosis, and ulcers.<sup>182,190,193,194</sup> The indications for obtaining APA testing are shown in Table XI.

## Interpretation of results

The results of APA testing should be interpreted with caution. Low levels may be of no clinical relevance and should not be interpreted as the cause of leg ulcers and purpura in every patient who has low levels of antibodies.<sup>195</sup>

## REFERENCES

1. Takeuchi Y, Ishikawa O, Miyachi Y. The comparative study of anti-double stranded DNA antibody levels measured by radioimmunoassay and enzyme-linked immunosorbent assay in systemic lupus erythematosus. *J Dermatol* 1997;24:297-300.
2. Krippner H, Merle S, Pirlot K. Enzyme immunoassay for IgG and IgM antibodies against dsDNA and ssDNA. *Z Rheumatol* 1983;42:256-60.
3. Wong KH, Lawton JWM, Cheng SKL, Lee SS, Lau CS. Measurement of anti-dsDNA: a comparative study of two ELISA and the Crithidia assay. *Pathology* 1998;30:57-61.
4. Spronk PE, Bootsma H, Kallenberg CGM. Anti-DNA antibodies as early predictor for disease exacerbations in SLE: guideline for treatment? *Clin Rev Allergy Immunol* 1998;16:211-8.
5. Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kencka D, et al. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. *Br J Dermatol* 1985;113:381-9.
6. Tuffanelli DL, Dubois EL. Cutaneous manifestations of systemic lupus erythematosus. *Arch Dermatol* 1964;90:377-86.
7. Cabral AR, Alarcón-Segovia D. Autoantibodies in systemic lupus erythematosus. *Curr Opin Rheumatol* 1998;10:409-16.
8. Pahor A, Krajnc I, Gorenjak M, Holc I. The clinical significance of antinuclear antibodies in connective tissue disease. *Wien Klin Wochenschr* 1998;110:338-41.
9. Tan EM, Feltkamp TEW, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. *Arthritis Rheum* 1997;40:1601-11.
10. Fernandez-Madrid F, Mattioli M. Antinuclear antibodies (ANA): immunologic and clinical significance. *Semin Arthritis Rheum* 1976;6:83-124.
11. Provost TT, Watson R. Antinuclear antibodies in systemic lupus erythematosus. In: Norris DA, editor. *Immune mechanisms in cutaneous disease*. New York: Marcel Dekker; 1989. p. 333-57.
12. Ward MM. Laboratory testing for systemic rheumatic diseases. *Postgrad Med* 1998;103:93-100.
13. Moder KG. Use and interpretation of rheumatologic tests: a guide for clinicians. *Mayo Clin Proc* 1996;71:391-6.
14. Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. *Adv Dermatol* 1991;7:3-52.
15. Hamburger M, Hodes S, Barland P. The incidence and clinical significance of antibodies to extractable nuclear antigens. *Am J Med Sci* 1977;273:21-8.
16. Field M, Williams DG, Charles P, Maini RN. Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens. *Ann Rheum Dis* 1988;47:820-5.
17. Fritzler MJ. Antinuclear antibodies in the investigation of rheumatic diseases. *Bull Rheum Dis* 1985;35:1-10.
18. Fritzler MJ. Clinical relevance of autoantibodies in systemic rheumatic diseases. *Mol Biol Rep* 1996;23:133-45.
19. Hietarinta M, Lassila O. Clinical significance of antinuclear antibodies in systemic rheumatic diseases. *Ann Med* 1996;28:283-91.
20. Provost TT. Subsets in systemic lupus erythematosus. *J Invest Dermatol* 1979;72:110-3.
21. Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. *Lupus* 1993;2:15-9.
22. Tomer Y, Buskila D, Shoenfeld Y. Pathogenic significance and diagnostic value of lupus autoantibodies. *Int Arch Allergy Immunol* 1993;100:293-306.
23. Combe B, Rucheton M, Graafland H, Lussiez V, Brunel C, Sany J. Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. *Clin Exp Immunol* 1989;75:18-24.
24. Gilliam JN, Prystowsky SD. Mixed connective tissue disease syndrome: cutaneous manifestations of patients with epidermal nuclear staining and high titer serum antibody to ribonuclease-sensitive extractable nuclear antigen. *Arch Dermatol* 1977;113:583-7.
25. Lundberg I, Hedfors E. Clinical course of patients with anti-RNP antibodies: a prospective study of 32 patients. *J Rheumatol* 1991;18:1511-9.
26. Hardin JA, Mimori T. Autoantibodies to ribonucleoproteins. *Clin Rheum Dis* 1985;11:485-505.
27. Juby AA, Johnston C, Davis P. Specificity, sensitivity and diagnostic predictive value of selected laboratory generated autoantibody profiles in patients with connective tissue diseases. *J Rheumatol* 1991;18:354-8.
28. de Rooij DJ, van de Putte LBA, Habets WJ, van Venrooij WJ. Marker antibodies in scleroderma and polymyositis: clinical associations. *Clin Rheumatol* 1989;8:231-7.
29. Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M. Anticentromere and anticentriole antibodies in the scleroderma spectrum. *Arch Dermatol* 1983;119:560-6.
30. Cook L. New methods for detection of anti-nuclear antibodies. *Clin Immunol Immunopathol* 1998;88:211-20.
31. de Rooij DJ, van de Putte LB, Habets WJ, Verbeek AL, van Venrooij WJ. The use of immunoblotting to detect antibodies

- to nuclear and cytoplasmic antigens: clinical and serological associations in rheumatic disease. *Scand J Rheumatol* 1988; 17:353-64.
32. Saitta MR, Keene JD. Molecular biology of nuclear antigens. *Rheum Dis Clin North Am* 1992;18:283-310.
  33. Walravens MJF, Vanherrewegen H, Lacquet F, Godefridis G, Korevits G, Stevens E, et al. Counterimmunoelectrophoresis with serum prediffusion: an improved method for the detection and identification of antibodies against extractable nuclear and cytoplasmic antigens. *J Immunol Methods* 1997; 201:89-98.
  34. Schur PH, DeAngelis D, Jackson JM. Immunological detection of nucleic acids and antibodies to nucleic acids and nuclear antigens by counterimmunoelectrophoresis. *Clin Exp Immunol* 1974;17:209-18.
  35. Kurata N, Tan EM. Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis. *Arthritis Rheum* 1976;19:574-80.
  36. Lange A, Jacak A, Garnsarek D. Diagnostic specificity of autoantibodies. IV. A double antibody solid phase radioimmunoassay for DNA antibodies: significance of dsDNA and ssDNA antibodies with test standardization attempts. *Arch Immunol Ther Exp (Warsz)* 1978;26:893-7.
  37. Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A, et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. *J Immunol Methods* 1998;219: 99-107.
  38. Evans J. Antinuclear antibody testing in systemic autoimmune disease. *Clin Chest Med* 1998;19:613-25.
  39. Gniewek RA, Stites DP, McHugh TM, Hilton JF, Nakagawa M. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. *Clin Diagn Lab Immunol* 1997;4:185-8.
  40. Tikly M, Burgin S, Mohanlal P, Bellingan A, George J. Autoantibodies in Black South Africans with systemic lupus erythematosus: spectrum and clinical associations. *Clin Rheumatol* 1996;15:261-5.
  41. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. *Medicine* 1993;72:113-24.
  42. Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. *Clin Immunol Immunopathol* 1985;36:120-8.
  43. Emlen W, Jarusiripipat P, Burdick G. A new ELISA for the detection of double-stranded DNA antibodies. *J Immunol Methods* 1990;132:91-101.
  44. Carey JL. Enzyme immunoassays for antinuclear antibodies. *Clin Lab Med* 1997;17:355-65.
  45. Bell DA, Smeenk RJT. Clinical connections: assays and assessment. *Lupus* 1997;6:305-6.
  46. Hahn BH. Antibodies to DNA. *N Engl J Med* 1998;338:1359-68.
  47. Levinson WE, Jawetz E. *Medical microbiology and immunology*. 2nd ed. Norwalk (CT): Appleton & Lange; 1992. p. 302-8.
  48. Lange A. Evaluation of the simultaneous estimation of anti-dsDNA and anti-ssDNA antibodies for clinical purposes. *Clin Exp Immunol* 1978;31:472-81.
  49. Chuan M-T, Wu Y-C, Tiak-de Ang E, Wang J-H, In K-L, Lü Y-C. Clinical significance of anti-nDNA antibodies in ANA-positive systemic lupus erythematosus: comparison of the Farr radioimmunoassay and the *Crithidia lucilliae* immunofluorescent technique. *Chin J Microbiol Immunol* 1985;18:15-24.
  50. Tourville DR, Benn V. Evaluation of a semiautomated pre-standardized immunofluorescence test system for detection of anti-native deoxyribonucleic acid antibodies. *J Clin Microbiol* 1978;7:219-22.
  51. Shen GO, Shoenfeld Y, Peter JB. Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. *Clin Rev Allergy Immunol* 1998;16: 321-34.
  52. Aarden LA, de Groot ER, Feltkamp TEW. Immunology of DNA. III. *Crithidia lucilliae*, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. *Ann NY Acad Sci* 1975;254:505-15.
  53. Ferman J, Dannon F, Brouet JC. Characterization of a human monoclonal IgM with antibody activity to dsDNA. *Clin Exp Immunol* 1985;59:467-74.
  54. Kumar V, Krasny S, Beutner EH. Specificity of the *Crithidia lucilliae* method for detecting anti-DNA antibodies: effect of absorption for lipoproteins. *Immunol Invest* 1985;14:199-210.
  55. Jansen EM, Deng J-S, Beutner EH, Kumar V, Chorzelski TP. Comparison of commercial kits for the detection of anti-nDNA antibodies using *Crithidia lucilliae*. *Am J Clin Pathol* 1987;87: 461-9.
  56. Cameron JS, Lessof MH, Ogg CS, Williams BD, Williams DG. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations: DNA-binding capacity and precipitating anti-DNA antibody. *Clin Exp Immunol* 1976;25:418-27.
  57. Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. *Leuk Lymphoma* 1992;7:117-22.
  58. Kaburaki J, Kuwana M, Ogasawara T, Takano M, Funatsu Y, Tojo T. Specificity of antibodies to single-stranded (ss) DNA in SLE patients with anti-phospholipid syndrome. *Keio J Med* 1992; 41:10-5.
  59. Williams WM, Isenberg DA. A cross-sectional study of anti-DNA antibodies in the serum and IgG and IgM fraction of healthy individuals, patients with systemic lupus erythematosus and their relatives. *Lupus* 1996;5:576-86.
  60. Callen JP, Fowler JF, Kulick KB. Serologic and clinical features of patients with discoid lupus erythematosus: relationship of antibodies to single-stranded deoxyribonucleic acid and of other antinuclear antibody subsets to clinical manifestations. *J Am Acad Dermatol* 1985;13:748-55.
  61. Sarvas H, Gripenberg M, Leirisalo-Repo M. Anti-DNA antibodies: the choice of assays for routine diagnostic work. *Acta Pathol Microbiol Immunol Scand Sect C* 1985;93:13-8.
  62. Buskila D, Berezin M, Gur H, Lin HC, Alosachie I, Terberry JW, et al. Autoantibody profile in the sera of women with hyperprolactinemia. *J Autoimmun* 1995;8:415-24.
  63. Falanga V, Medsger TA, Reichlin M. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. *Arch Dermatol* 1987;123:350-3.
  64. Gripenberg M, Helve T, Kurki P. Profiles of antibodies to histones, DNA and IgG in patients with systemic rheumatic diseases determined by ELISA. *J Rheumatol* 1985;12:934-9.
  65. Falanga V, Medsger TA, Reichlin M. High titers of antibodies to single-stranded DNA in linear scleroderma. *Arch Dermatol* 1985;121:345-7.
  66. Yadin O, Sarov B, Naggan L, Shoenfeld Y. Familial studies on the occurrence of natural autoantibodies. *Nat Immun Cell Growth Regul* 1989;8:325-30.
  67. Rubin RL, Waga S. Antihistone antibodies in systemic lupus erythematosus. *J Rheumatol* 1987;14(Suppl 13):118-26.
  68. Monestier M, Kotzin BL. Antibodies to histones in systemic lupus erythematosus and drug-induced lupus syndromes. *Rheum Dis Clin North Am* 1992;18:415-36.
  69. Grossman L, Barland P. Histone reactivity of drug-induced antinuclear antibodies. *Arthritis Rheum* 1981;24:927-31.
  70. Portanova JP, Rubin RL, Joslin FG, Agnello VD, Tan EM.

- Reactivity of anti-histone antibodies induced by procainamide and hydralazine. *Clin Immunol Immunopathol* 1982;25:67-79.
71. Craft JE, Radding JA, Harding MW, Bernstein RM, Hardin JA. Autoantigenic histone epitopes: a comparison between procainamide- and hydralazine-induced lupus. *Arthritis Rheum* 1987;30:689-94.
  72. Teoh PC, Chan HL. Lupus-scleroderma syndrome induced by ethosuximide. *Arch Dis Child* 1975;50:659-61.
  73. Sato-Matsumura KC, Koizumi H, Matsumura T, Takahashi T, Adachi K, Ohkawara A. Lupus erythematosus-like syndrome induced by thiamazole and propylthiouracil. *J Dermatol* 1994;21:501-7.
  74. Agarwal MB, Anjaria PD, Mehta BC. Activation of systemic lupus erythematosus by antitubercular drugs. *J Postgrad Med* 1980;26:263-6.
  75. Timsit M-A, Anglicheau D, Lioté F, Marteau P, Dryll A. Mesalazine-induced lupus. *Rev Rhum Engl Ed* 1997;64:586-8.
  76. Condemni JJ. SLE: idiopathic or drug-induced? *Geriatrics* 1980;35:81-8.
  77. Price EJ, Venables PJW. Drug-induced lupus. *Drug Safety* 1995;12:283-90.
  78. Hobbs RN, Clayton A-L, Bernstein RM. Antibodies to the five histones and poly(adenosine diphosphate-ribose) in drug induced lupus: implications for pathogenesis. *Ann Rheum Dis* 1987;46:408-16.
  79. Stratton MA. Drug-induced systemic lupus erythematosus. *Clin Pharm* 1985;4:657-63.
  80. Roura M, Lopez-Gil F, Umberto P. Systemic lupus erythematosus exacerbated by piroxicam. *Dermatologica* 1991;182:56-8.
  81. Gigli GL, Scalise A, Pauri F, Silvestri G, Diomedì M, Placidi F, et al. Valproate-induced systemic lupus erythematosus in a patient with partial trisomy of chromosome 9 and epilepsy. *Epilepsia* 1996;37:587-8.
  82. Knights SE, Leandro MJ, Khamashta MA, Hughes GRV. Minocycline-induced arthritis. *Clin Exp Rheumatol* 1998;16:587-90.
  83. Yung RL, Richardson BC. Drug-induced lupus. *Rheum Dis Clin North Am* 1994;20:61-86.
  84. Tan EM, Portanova JP. The role of histones as nuclear autoantigens in drug-related lupus erythematosus. *Arthritis Rheum* 1981;24:1064-9.
  85. Portanova JP, Cheronis JC, Blodgett JK, Kotzin BL. Histone autoantigens in murine lupus: definition of a major epitope within an accessible region of chromatin. *J Immunol* 1990;144:4633-40.
  86. Fishbein E, Alarcon-Segovia D, Vega JM. Antibodies to histones in systemic lupus erythematosus. *Clin Exp Immunol* 1979;36:145-50.
  87. Burlingame RW. The clinical utility of antihistone antibodies. *Clin Lab Med* 1997;17:367-78.
  88. Aitkaci A, Monier JC, Mamelle N. Enzyme-linked immunosorbent assay for anti-histone antibodies and their presence in systemic lupus erythematosus sera. *J Immunol Methods* 1981;44:311-22.
  89. Shoenfeld Y, Segol O. Anti-histone antibodies in SLE and other autoimmune diseases. *Clin Exp Rheumatol* 1989;7:265-71.
  90. Fritzier MJ, Tan EM. Antibodies to histones in drug-induced and idiopathic lupus erythematosus. *J Clin Invest* 1978;62:560-7.
  91. Weinstein A. Drug-induced systemic lupus erythematosus. *Prog Clin Immunol* 1980;4:1-21.
  92. Craft J. Antibodies to snRNPs in systemic lupus erythematosus. *Rheum Dis Clin North Am* 1992;18:311-35.
  93. ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CGM. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. *Semin Arthritis Rheum* 1990;20:164-73.
  94. Habets WJ, Hoet MH, van Venrooij WJ. Epitope patterns of anti-RNP antibodies in rheumatic diseases. *Arthritis Rheum* 1990;33:834-41.
  95. Simmons-O'Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. *Medicine* 1995;74:109-30.
  96. Provost TT, Watson R, Simmons-O'Brien E. Significance of the anti-Ro(SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. *J Am Acad Dermatol* 1996;35:147-69.
  97. Ben-Chetrit E. Anti Ro/La antibodies and their clinical association. *Isr J Med Sci* 1997;33:251-3.
  98. Ben-Chetrit E, Chan EKL, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. *J Exp Med* 1988;167:1560-71.
  99. Deutscher SL, Harley JB, Keene JD. Molecular analysis of the 60-kDa human Ro ribonucleoprotein. *Proc Natl Acad Sci U S A* 1988;85:9479-83.
  100. Dickey WD, van Egmond JE, Hardgrave KL, Harley JB, Scofield RH. Presence of anti-La(SS-B) is associated with binding to the 13-kD carboxyl terminus of 60-kD Ro(SS-A) in systemic lupus erythematosus. *J Invest Dermatol* 1993;100:412-6.
  101. Alexander EL, McNicholl J, Watson RM, Bias W, Reichlin M, Provost TT. The immunogenetic relationship between anti-Ro(SS-A)/La(SS-B) antibody positive Sjögren's/lupus erythematosus overlap syndrome and the neonatal lupus syndrome. *J Invest Dermatol* 1989;93:751-6.
  102. St Clair EW. Anti-La antibodies. *Rheum Dis Clin North Am* 1992;18:359-76.
  103. Habets WJ, de Rooij DJ, Hoet MH, van de Putte LB, van Venrooij WJ. Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. *Clin Exp Immunol* 1985;59:457-66.
  104. Homma M, Mimori T, Takeda Y, Akama H, Yoshida T, Ogasawara T, et al. Autoantibodies to the Sm antigen: immunological approach to clinical aspects of systemic lupus erythematosus. *J Rheumatol* 1987;14(Suppl 13):188-93.
  105. Pollard KM, Tan EM. Purification of the Sm nuclear autoantigen: detection and clinical significance of IgM antibody. *Clin Exp Immunol* 1985;60:586-96.
  106. Gibbons JJ, Augustynek D, Tsai CC, Roodman ST. Characterization of RNP and Sm ribonucleoprotein nuclear antigens. *Mol Immunol* 1982;19:765-77.
  107. Beaufrils M, Kouki F, Mignon F, Camus J-P, Morel-Maroger L, Richet G. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. *Am J Med* 1983;74:201-5.
  108. Provost TT, Talal N, Harley JB, Reichlin M, Alexander E. The relationship between anti-Ro (SS-A) antibody-positive Sjögren's syndrome and anti-Ro (SS-A) antibody-positive lupus erythematosus. *Arch Dermatol* 1988;124:63-71.
  109. Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sjögren's syndrome and systemic lupus erythematosus. *Rheum Dis Clin North Am* 1992;18:337-58.
  110. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. *Ann Intern Med* 1982;97:664-71.
  111. Meyer O. Anti-Ro (SS-A). *Rev Rheum Engl Ed* 1998;65:85-8.
  112. Froelich CJ, Wallman J, Skosey JL, Teodorescu M. Clinical value of an integrated ELISA system for the detection of 6 autoantibodies (ssDNA, dsDNA, Sm, RNP/Sm, SSA, and SSB). *J Rheumatol* 1990;17:192-200.
  113. Alexander EL, Hirsch TJ, Arnett FC, Provost TT, Stevens MB.

- Ro(SSA) and La(SSB) antibodies in the clinical spectrum of Sjögren's syndrome. *J Rheumatol* 1982;9:239-46.
114. Wermuth DJ, Geoghegan WD, Jordon RE. Anti-Ro/SSA antibodies: association with a particulate (large speckledlike thread) immunofluorescent nuclear staining pattern. *Arch Dermatol* 1985;121:335-8.
  115. Reichlin M, Wasicek CA. Clinical and biologic significance of antibodies to Ro/SSA. *Hum Pathol* 1983;14:401-5.
  116. Maddison PJ, Isenberg DA, Goulding NJ, Leddy J, Skinner RP. Anti La (SSB) identifies a distinctive subgroup of systemic lupus erythematosus. *Br J Rheumatol* 1988;27:27-31.
  117. Doré N, Synkowski D, Provost TT. Antinuclear antibody determinations in Ro(SSA)-positive, antinuclear antibody-negative lupus and Sjögren's syndrome patients. *J Am Acad Dermatol* 1983;8:611-5.
  118. Kulick KB, Mogavero H Jr, Provost TT, Reichlin M. Serologic studies in patients with lupus erythematosus and psoriasis. *J Am Acad Dermatol* 1983;8:631-4.
  119. Zimmermann C, Smolen JS, Graninger W, Petera P, Fabini G, Hassfeld W, et al. Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. *J Rheumatol* 1996;23:1897-903.
  120. Dörner T, Hiepe F, Mielke F, Kiessig ST, Lukowsky A, Apostoloff E. Development of a solid phase enzyme immunoassay for the detection of anti-Ro autoantibodies. *Scand J Rheumatol* 1991;20:267-73.
  121. Maddison PJ. Anti-Ro antibodies and neonatal lupus. *Clin Rheumatol* 1990;9:116-22.
  122. Bell DA, Maddison PJ. Serologic subsets in systemic lupus erythematosus. *Arthritis Rheum* 1980;23:1268-73.
  123. Wechsler HL, Stavrides A. Systemic lupus erythematosus with anti-Ro antibodies: clinical, histologic, and immunologic findings. *J Am Acad Dermatol* 1982;6:73-83.
  124. Lee LA, Alvarez K, Gross T, Harley JB. The recognition of human 60-kDa Ro ribonucleoprotein particles by antibodies associated with cutaneous lupus and neonatal lupus. *J Invest Dermatol* 1996;107:225-8.
  125. Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. *Arch Dermatol* 1994;130:1262-8.
  126. Valeski JE, Kumar V, Forman AB, Beutner EH, Chorzelski TP. A characteristic cutaneous direct immunofluorescent pattern associated with Ro(SS-A) antibodies in subacute cutaneous lupus erythematosus. *J Am Acad Dermatol* 1992;27:194-8.
  127. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). *Am J Med* 1972;52:149-59.
  128. Provost TT, Watson R, Gaither KK, Harley JB. The neonatal lupus erythematosus syndrome. *J Rheumatol* 1987;14:199-205.
  129. Provost TT, Watson R, Gammon WR, Radowsky M, Harley JB, Reichlin M. The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. *N Engl J Med* 1987;316:1135-8.
  130. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. *Br J Rheumatol* 1998;37:15-20.
  131. Riboldi P, Asero R, Origgi L, Crespi S, Meroni PL, Sguotti C, et al. Antinuclear antibodies in progressive systemic sclerosis. *Clin Exp Rheumatol* 1985;3:205-11.
  132. Igarashi A, Takehara K, Soma Y, Kikuchi K, Ishibashi Y. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis. *Dermatologica* 1990;180:136-40.
  133. Tanimoto K. MCTD (mixed connective tissue disease). *Nippon Rinsho* 1994;52:2120-2.
  134. Abuaf N, Johanet C, Chretien P, Absalon BI, Homberg JC, Buri JF. Detection of autoantibodies to Sm antigen in systemic lupus erythematosus by immunodiffusion, ELISA and immunoblotting: variability of incidence related to assays and ethnic origin of patients. *Eur J Clin Invest* 1990;20:354-9.
  135. López-Longo FJ, Monteagudo I, González CM, Moreno AC, Mahou MR, Grau R, et al. Anti-BB'-Sm antibodies, anticardiolipin antibodies, and thrombosis in systemic lupus erythematosus. *J Rheumatol* 1998;25:1743-9.
  136. Gripenberg M, Teppo A-M, Friman C. Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. *Rheumatol Int* 1991;11:209-13.
  137. Swaak AJG, Huysen V, Smeenk RJT. Antinuclear antibodies in routine analysis: the relevance of putative clinical associations. *Ann Rheum Dis* 1993;52:110-4.
  138. Hildebrandt S, Noell GS, Vazquez-Abad D, Earnshaw WC, Zanetti M, Rothfield NF. Idiopathic analysis of human anti-topoisomerase I autoantibodies. *Autoimmunity* 1991;10:41-8.
  139. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC. Antibodies to topoisomerase I in sera from patients with scleroderma. *J Rheumatol* 1987;14(Suppl 13):138-40.
  140. Juarez C, Vila JL, Gelpi C, Agusti M, Amengual MJ, Martinez MA, et al. Characterization of the antigen reactive with anti-Scl-70 antibodies and its application in an enzyme-linked immunosorbent assay. *Arthritis Rheum* 1988;31:108-15.
  141. Catoggio LJ, Skinner RP, Maddison PJ. Frequency and clinical significance of anticentromere and anti-Scl-70 antibodies in an English connective tissue disease population. *Rheumatol Int* 1983;3:19-21.
  142. Rothfield NF. Autoantibodies in scleroderma. *Rheum Dis Clin North Am* 1992;18:483-98.
  143. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody: a specific marker of systemic sclerosis. *Br J Dermatol* 1986;115:393-401.
  144. Aeschlimann A, Meyer O, Bourgeois P, Haim T, Belmatoug N, Palazzo E, et al. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. *Ann Rheum Dis* 1989;48:992-7.
  145. Nishikal M, Ohya K, Kosaka M, Akiya K, Tojo T. Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. *Br J Rheumatol* 1998;37:357-61.
  146. Vázquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. *Arthritis Rheum* 1996;39:292-6.
  147. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. *Arthritis Rheum* 1983;26:604-11.
  148. Targoff IN. Autoantibodies in polymyositis. *Rheum Dis Clin North Am* 1992;18:455-82.
  149. Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Turner-Warwick M, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. *Br Med J* 1984;289:151-2.
  150. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. *J Rheumatol* 1984;11:663-5.
  151. Rowell NR, Beck JW. The diagnostic value of an antinuclear antibody test in clinical dermatology. *Arch Dermatol* 1967;96:290-5.
  152. Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. *Arch Dis Child* 1997;77:299-304.
  153. Xavier RM, Yamauchi Y, Nakamura M, Tanigawa Y, Ishikura H, Tsunematsu T, et al. Antinuclear antibodies in healthy aging people: a prospective study. *Mech Ageing Dev* 1995;78:145-54.

154. Kiuttu J, Hartikainen AL, Makitalo R, Ruuska P. The outcome of pregnancy in antinuclear antibody-positive women. *Gynecol Obstet Invest* 1994;37:160-3.
155. Kiuttu J, Hartikainen-Sorri AL, Makitalo R. Occurrence of antinuclear antibodies in an unselected pregnancy population. *Gynecol Obstet Invest* 1992;33:21-5.
156. Maddison PJ, Skinner RP, Pereira RS, Black CM, Ansell BM, Jayson M IV, et al. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. *Ann Rheum Dis* 1986;45:793-9.
157. Wilson JD. Antinuclear antibodies and cardiovascular drugs. *Drugs* 1980;19:292-305.
158. Blaszczyk M, Jarzabek-Chorzelska M, Jablonska S, Chorzelski T, Kolacinska-Strasz Z, Beutner EH, et al. Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations. *Br J Dermatol* 1990;123:421-30.
159. Bernstein RM, Steigerwald JC, Tan EM. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. *Clin Exp Immunol* 1982;48:43-51.
160. Kleinsmith DM, Heinzerling RH, Burnham TK. Antinuclear antibodies as immunologic markers for a benign subset and different clinical characteristics of scleroderma. *Arch Dermatol* 1982;118:882-5.
161. Burnham TK. Antinuclear antibodies: a simplified classification of the nuclear immunofluorescent patterns. *Arch Dermatol* 1978;114:1343-4.
162. Maddison PJ, Provost TJ, Reichlin M. Serological findings in patients with "ANA-negative" systemic lupus erythematosus. *Medicine* 1981;60:87-94.
163. Ahmed AR, Workman S. ANA-negative systemic lupus erythematosus. *Clin Exp Dermatol* 1983;8:369-77.
164. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing: a study of clinical utility. *Arch Intern Med* 1996;156:1421-5.
165. Fries JF, Porta J, Liang MH. Marginal benefit of renal biopsy in systemic lupus erythematosus. *Arch Intern Med* 1978;138:1386-9.
166. Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P. Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. *J Rheumatol* 1998;25:1980-5.
167. Sulcebe G, Morcka K. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases. *Clin Exp Rheumatol* 1992;10:255-61.
168. Fletcher RH, Fletcher SW, Wagner EH. *Clinical epidemiology: the essentials*. 2nd ed. Baltimore: Williams & Wilkins; 1988. p. 42-75.
169. Jaskowski TD, Schroder C, Martins TB, Mouritsen CL, Litwin CM, Hill HR. Screening for antinuclear antibodies by enzyme immunoassay. *Am J Clin Pathol* 1996;105:468-73.
170. Kallenberg CGM. Anti-centromere antibodies (ACA). *Clin Rheumatol* 1990;9:136-40.
171. Chen Z, Fedrick JA, Pandey JP, Silver R, Maricq HR, Fudenberg H, et al. Anticentromere antibody and immunoglobulin allotypes in scleroderma. *Arch Dermatol* 1985;121:339-44.
172. Witte T, Hartung K, Sachse C, Matthias T, Fricke M, Deicher H, et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. *Rheumatol Int* 1998;18:85-91.
173. Harris EN, Gharavi AE, Hughes GRV. Anti-phospholipid antibodies. *Clin Rheum Dis* 1985;11:591-609.
174. Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. *Ann Rheum Dis* 1989;48:362-7.
175. Meroni PL, Tincani A, Harris EN, Valesini G, Hughes GRV, Balestrieri G. The pathophysiology of anti-phospholipid antibodies. *Clin Exp Rheumatol* 1989;7(Suppl 3):81-4.
176. Mackworth-Young C. Antiphospholipid antibodies: more than just a disease marker? *Immunol Today* 1990;11:60-5.
177. Aillaud MF, Reviron D, Alessi MC, Harle JR, Amiral J, Juhan-Vague I. Lupus anticoagulants and antiphospholipid antibodies: comparison of clotting tests with an immunological assay. *Thromb Res* 1990;60:181-3.
178. Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. *Clin Exp Immunol* 1984;56:193-9.
179. Colaço CB, Male DK. Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity. *Clin Exp Immunol* 1985;59:449-56.
180. Watson KV, Schorer AE. Lupus anticoagulant inhibition of *in vitro* prostacyclin release is associated with a thrombosis-prone subset of patients. *Am J Med* 1991;90:47-53.
181. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using  $\beta_2$ -glycoprotein I as an antigen. *J Immunol Methods* 1991;143:223-9.
182. Bick RL. Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. *Int J Hematol* 1997;65:193-213.
183. Le Tonquèze M, Dueymes M, Giovannardi Y, Beigbeder G, Jouquan J, Pennec Y-L, et al. The relationship of anti-endothelial cell antibodies to anti-phospholipid antibodies in patients with giant cell arteritis and/or polymyalgia rheumatica. *Autoimmunity* 1995;20:59-66.
184. Toschi V, Motta A, Castelli C, Gibelli S, Cimminiello C, Molaro GL, et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. *Haemostasis* 1993;23:275-83.
185. Shieh M-T, Pierce C, Bartholomew W, Kumar V. Anti-phospholipid antibody profiles of different specificities in syphilis and systemic lupus erythematosus. *Immunol Invest* 1990;19:507-18.
186. Thomas MAB, Frampton G, Isenberg DA, Shoenfeld Y, Akinsola A, Ramzy M, et al. A common anti-DNA antibody idiomorph and anti-phospholipid antibodies in sera from patients with schistosomiasis and filariasis with and without nephritis. *J Autoimmun* 1989;2:803-11.
187. Labarca JA, Rabagliati RM, Radrigan FJ, Rojas PP, Perez CM, Ferrés MV, et al. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. *Clin Infect Dis* 1997;24:197-200.
188. Maclean C, Flegg PJ, Kilpatrick DC. Anti-cardiolipin antibodies and HIV infection. *Clin Exp Immunol* 1990;81:263-6.
189. Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. *Hepatology* 1996;23:199-204.
190. Grob JJ, San Marco M, Aillaud MF, Andrac L, Gabriel B, Juhan-Vague I, et al. Unfading acral livedo. *J Am Acad Dermatol* 1991;24:53-8.
191. Barbui T, Finazzi G, Galli M, Ciavarella N, Schiavoni M, Palareti G, et al. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. *Haematologica* 1993;78:313-8.
192. De Bandt M, Benali K, Guillevin L, Hachulla E, Job C, Fautrel B, et al. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome: a prospective study. *J Rheumatol* 1999;26:91-6.

- Occlusive vasculopathy in systemic lupus erythematosus. *Arch Intern Med* 1991;151:389-92.
194. Asherson RA, Mayou SC, Merry P, Black MM, Hughes GR. Spectrum of livedo reticularis and anticardiolipin antibodies. *Br J Dermatol* 1989;120:215-22.
195. Maneta-Peyret L, Previsani C, Sultan Y, Beziau J-H, Cassagne C. Autoantibodies against all the phospholipids: a comparative systematic study with systemic lupus erythematosus and healthy sera. *Eur J Clin Chem Clin Biochem* 1991;29:39-43.
196. Vlachoyiannopoulos PG, Tzavara V, Dafni U, Spanos E, Moutsopoulos HM. Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic. *J Rheumatol* 1998;25:886-91.
197. Gleicher N. Autoantibodies in normal and abnormal pregnancy. *Am J Reprod Immunol* 1992;28:269-73.
198. Lo SCL, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG. Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant. *Br J Haematol* 1990;76:380-6.

---

## Answers to CME examination

Identification No. 800-102

February 2000 issue of the Journal of the American Academy of Dermatology

Questions 1-29, Mutasim DF, Adams BB. *J Am Acad Dermatol* 2000;42:159-74.

- |       |       |
|-------|-------|
| 1. c  | 16. c |
| 2. c  | 17. a |
| 3. c  | 18. c |
| 4. b  | 19. c |
| 5. b  | 20. a |
| 6. d  | 21. a |
| 7. e  | 22. a |
| 8. c  | 23. c |
| 9. d  | 24. a |
| 10. e | 25. d |
| 11. b | 26. a |
| 12. d | 27. e |
| 13. d | 28. b |
| 14. b | 29. c |
| 15. d |       |

---

## CME examination

Identification No. 800-102

Instructions for Category I CME credit appear in the front advertising section. See last page of Contents for page number.

Questions 1-29, Mutasim DF, Adams BB. J Am Acad Dermatol 2000;42:159-74.

Directions for questions 1-13: Give single best response.

- Each of the following is true about antibodies in connective tissue diseases *except*
  - the total amount of antibodies in a patient's serum is usually indicated by the titer.
  - the specificity of each of the antibodies varies.
  - antibodies are not found in healthy persons.
  - the total amount of antibodies is larger in patients with connective tissue diseases compared with others.
  - each connective tissue disease has a unique profile of antibodies.
- Which of the following is true regarding radial immunodiffusion?
  - It is less sensitive and less specific than enzyme-linked immunosorbent assay (ELISA).
  - It is less sensitive and less specific than immunofluorescence.
  - The diagnostic value of a positive test by radial immunodiffusion is higher than that by ELISA.
  - Radial immunodiffusion will be positive even when small amounts of antibodies are presented.
  - It is less subjective than ELISA.
- Each of the following connective tissue disorders demonstrates a high incidence of anti-Ro(SS-A) antibodies *except*
  - neonatal lupus erythematosus (LE)
  - antinuclear antibody (ANA)-negative systemic LE (SLE)
  - discoid LE
  - mothers of infants with neonatal LE
  - Homozygous C2 or C4 deficiency
- Compared with radial immunodiffusion, characteristics of ELISA testing include each of the following *except*
  - sensitive test
  - specific test
  - less labor intensive
  - easy to screen large number of sera together
  - less subjective
- Which of the following is not an antibody to small ribonucleoproteins?
  - Anti-Ro(SS-A) antibody
  - Antihistone antibody
  - Anti-nuclear ribonucleoprotein
  - Anti-Sm antibody
  - Anti-La(SS-B) antibody
- Each of the following is true regarding native DNA (nDNA) antibodies *except*
  - the ELISA for nDNA is more sensitive than indirect immunofluorescence.
  - nDNA antibodies are characteristic of SLE.
  - nDNA antibodies are associated with renal disease.
  - nDNA antibodies detected by ELISA are diagnostic of SLE.
  - the indirect immunofluorescence test is performed on *Crithidia*.
- Each of the following statements is true *except*
  - anti-Ro(SS-A) antibodies are associated with photosensitivity.
  - anti-Ro(SS-A) antibodies are associated with subacute cutaneous LE.
  - there is a genetic disposition for the presence of anti-Ro(SS-A) antibodies.
  - anti-Ro(SS-A) antibodies are common in neonatal LE.
  - anti-Ro(SS-A) antibodies can be detected reliably by the fluorescent ANA test.
- Anti-Jo-1 antibodies are directed against
  - topoisomerase
  - gyrase
  - histidyl transfer RNA synthetase
  - phospholipase
  - lysyl oxidase
- ANA is *least* useful in evaluating
  - patients with photosensitivity
  - patients with chronic vasculitis
  - patients undergoing phototherapy
  - patients with facial eruptions
  - patients with discoid LE
- HEp-2 cells, used by many laboratories as a substrate for ANA testing, are obtained from
  - mouse kidney
  - rat liver
  - hybridomas
  - rat bladder
  - cultured human cells
- Which of the following statements about the ANA test is correct?
  - The diagnostic value of the ANA test does not depend on the clinical presentation.

- b. The positive predictive value of the ANA test for SLE is low.
  - c. The negative predictive value of the ANA test for SLE is low.
  - d. The marginal benefit of the ANA test is maximal when the pretest probability is low.
  - e. Tests with high sensitivity will have high predictive value when positive.
12. Regarding antiphospholipid antibodies, which of the following statements is true?
- a. The sensitivity of the ELISA is low.
  - b. These antibodies are not related to false-positive VDRL.
  - c. They are associated with a bleeding diathesis.
  - d. In vitro these antibodies delay the coagulation pathway.
  - e. These antibodies are directed against positively charged phospholipids.
13. Cutaneous manifestations of antiphospholipid antibody syndrome include each of the following *except*
- a. livedo reticularis
  - b. ulcers
  - c. purpura
  - d. calcinosis
  - e. necrosis

*Directions for questions 14-17: For each numbered item, select the one lettered item that reflects the incidence of anti-Ro(SS-A) antibodies by radial immunodiffusion (each letter may be used once, more than once, or not at all).*

- a. <5%
  - b. 50%
  - c. 70%
  - d. 95%
14. Sjögren's syndrome
15. Neonatal LE
16. Subacute cutaneous LE
17. Systemic sclerosis

*Directions for questions 18-20: For each numbered ANA pattern, select the one lettered answer that reflects the antigen closely associated with the ANA pattern (each letter may be used once, more than once, or not at all).*

- a. Kinetochore
  - b. Single-stranded DNA
  - c. Double-stranded DNA
18. Peripheral
19. Homogeneous
20. Centromere

*Directions for questions 21-24: For each numbered ANA pattern, select the one lettered item most closely related (each letter may be used once, more than once, or not at all).*

- a. SLE
  - b. Mixed connective tissue disease
  - c. CREST syndrome
  - d. Dermatomyositis
21. Peripheral
22. Homogeneous
23. Centromere
24. Nucleolar

*Directions for questions 25-29: For each numbered item, select the one lettered item most closely related (each letter may be used once, more than once, or not at all).*

- a. Anti-Jo-1 antibodies
  - b. Anti-Ro(SS-A) antibodies
  - c. Anti-Sci-70 antibodies
  - d. nRNP antibodies
  - e. Antihistone antibodies
25. Mixed connective tissue disease
26. Dermatomyositis
27. Drug-induced SLE
28. Neonatal LE
29. Systemic sclerosis